People | October 13, 2025
Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
US FDA approval based on NEURO-TTRansform Phase III results
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Subscribe To Our Newsletter & Stay Updated
